Thelansis

Recurrent C. Difficile Infections (rCDI) Market Outlook Thelansis’s “Recurrent C. Difficile Infections (rCDI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent C. Difficile Infections (rCDI) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will h...

Recurrent C. Difficile Infections (rCDI) Market Outlook Thelansis’s “Recurrent C. Difficile Infections (rCDI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent C. Difficile Infections (rCDI) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Recurrent C. Difficile Infections (rCDI) Overview Clostridium difficile infection (CDI) is an anaerobic spore-forming bacillus that colonizes the intestinal tract in patients whose normal gut microbiota is disrupted by antibiotic therapy or any other reason. C difficile produces two major toxins—toxins A and B—that cause intestinal mucosal injury, diarrhea, and colitis. In some cases,...

  Clostridium difficile infection (CDI) is an anaerobic spore-forming bacillus that colonizes the intestinal tract in patients whose normal gut microbiota is disrupted by antibiotic therapy or any other reason. C difficile produces two major toxins—toxins A and B—that cause intestinal mucosal injury, diarrhea, and colitis. In some cases, fulminant infection leads to shock, ileus, and toxic megacolon. In high-income countries, C. difficile is the most common cause of infectious diarrhea in hospitalized patients. Between 20% and 35% of patients with C. difficile infection will fail initial antibiotic treatment, and, of these, 40–60% will have a second recurrence. Recurrence of C. difficile infection after initial treatment causes substantial morbidity and is a significant burden on health care systems. Antibiotics are the mainstay treatments for primary and recurrent CDI, with a recent trend toward vancomycin and fidaxomicin over metronidazole. Recurrent infections affect 15-35 perce...